Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy

East African Medical Journal

Volumn 74, Issue 9, 1997, Pages 543-548

  Schwander, S K ^a,b,f   Dietrich, M ^c   Mugyenyi, P ^a   Kityo, C ^a   Okwera, A ^d   Johnson, J ^b   Nsubuga, P ^e   Ruesch Gerdes, S ^d   Whalen, C ^b  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d Mulago National Hospital   (Uganda)

^e RESEARCH CENTER BORSTEL   (Germany)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; AFRICA SOUTH OF THE SAHARA; AGE; AGED; AIDS RELATED COMPLEX; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DEMOGRAPHIC FACTORS; DEVELOPING COUNTRY; DISEASE COURSE; DISEASES; EASTERN AFRICA; ENGLISH SPEAKING AFRICA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFECTIONS; LUNG TUBERCULOSIS; MALE; MIDDLE AGED; POPULATION; POPULATION AND POPULATION RELATED PHENOMENA; PREDICTION AND FORECASTING; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RESEARCH REPORT; SURVIVAL; TREATMENT; TUBERCULIN TEST; TUBERCULOSIS; UGANDA; VIRAL DISEASES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICA; AFRICA SOUTH OF THE SAHARA; AGE FACTORS; DEMOGRAPHIC FACTORS; DEVELOPING COUNTRIES; DISEASES; EASTERN AFRICA; ENGLISH SPEAKING AFRICA; HIV INFECTIONS; INFECTIONS; POPULATION; POPULATION CHARACTERISTICS; RESEARCH REPORT; TREATMENT; TUBERCULOSIS; UGANDA; VIRAL DISEASES;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RIFAMPIN; SURVIVAL ANALYSIS; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; UGANDA;

EID: 0031217146     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Patel, K.B., Belmonte, R. and Crowe, H.M. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N. Engl. J. Med. 1995; 332:336-7.
2. Peloquin, C.A., MacPhee, A.A. and Berning, S.E. Malabsorption of antimyeobacterial medications. N. Engl. J. Med. 1993; 329:1122-3.
3. Berning, S.E., Huitt, G.A., Iseman M.D. and Peloquin, C.A. Malahsorption of antimycobacterial medications by a patient with AIDS. N. Engl. J. Med. 1992; 327:1817-18.
4. Weis, S.E., Slocum, P.C., Blais F.X., King, B., Nunn, M., Matney, G.B., Gomez, E. and Foresman, B.H. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994; 330:1179-84.
5. Mitchinson, DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Amer. Rev Respir Dis. 1993; 147:1062-1063.
6. Smith, R.L., Yew K., Berkowitz K.A. and Aranda C.P. Factors affecting the yield of acid-fast sputum smears in patients with HIV and Tuberculosis. Chest. 1994; 106:684-86.
7. Elliot, A.M., Namaambo, K., Allen, B.W., Lio N., Pobee, J.O.M. and McAdam, K.P.W.J. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis. 1993; 74:191-194.
8. Batungwanayo, J., Taelman, H. and Dhote, R. Pulmonary tuberculosis in Kigali, Rwanda. Amer. Rev Respir. Dis. 1992; 146: 53-55
9. Small, P.E., Hopewell, P.C. and Scheeler, G.F. Evolution of Chest Radiographs in Treated Patients with Pulmonary Tuberculosis and HIV Infection. J. Thoracic Imaging. 1994; 9:74-77.
10. Schwander, S.K., Ruesch-Gerdes, S., Mateega, A., Lutalo, T., Tugume, S., Aisu, T., Kityo, C., Rubaramira, R., Mugerwa, R., Okwera, A., Moser, R., Ochen, K., Mugyenyi, P., M'Bonye, B. and Dietrich, M. A Pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the Treatment of HIV-associated tuberculosis. A single blinded randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuberc. Lung Dis. 1995; 76:210-218.
11. Karnofsky, D.A. and Burchenal, J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press. 1949; 191-205.
12. Falk, A., O'Connor, J.B., Pratt, P.C., Webb, W.R., Wier. J.A. and Wolinsky, E. Classification of pulmonary Tuberculosis: Diagnostic Standards and Classification of Tuberculosis 1969. chapter 6. New York: National Tuberculosis and Respiratory Disease Association.
13. Morris, C.D.W., Bird, A.R. and Nell, H. The haemutological and biochemical Changes in severe pulmonary tuberculosis. Quart. J. Med. 1989; 272:1151-1159.
14. Laehdevirta, J., Maury, C.P.J., Teppo, A.M. and Repo, H. Elevated levels of circulating Cachectin/Tumor Necrosis Factor in Patients with Acquired Immunodeficiency Syndrome. Amer. J. Med. 1988; 85:289-291.
15. Aukrust, P., Liabakk, N.B., Mueller, F., Lien, E., Espevik, T. and Froland, S.S. Serum levels of tumor necrosis factor-α (TNFα) and soluble TNF receptors in Human Immunodeficiency virus Type 1 infection - correlations to clinical, immunologic, and virologic parameters. J. Infect. Dis. 1994; 169:420-4.
16. Kim, S.J., Kim, H.I., Lee, Y.H. and Kim, S.K. Production of Tumor necrosis factor-alpha by alveolar macrophages from patients with pulmonary tuberculosis. J. Korean Med. Sci. 1991; 6;45-53.
17. Wallis, R.S., Vjecha, M., Amir-Tahmasseb, M., Okwera, A., Byekwaso, F., Nyole, S., Kabengera, S., Mugerwa, R.D. and Ellner. J.J. Influence of tuberculosis on human immunodeficiency virus. (HIV-1) enhanced cytokine expression and elevated β2-microglobulin in HIV-1 associated tuberculosis. J. Infect. Dis. 1993; 167:43-48.
18. Kettelhut, I.C. and Goldberg, A.L. Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue. J. Clin. Invest. 1988; 81: 1384-9
19. Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D, Kiefer, D. and Vuocolo, G. Tumors secreting Human TNF/Cachectin Induce Cachexia in Mice. Cell. 1987; 50: 555-563.
20. Tracey, K.J., Wet, H., Manogue, K.R., Fong, Y., Hesse, D.G., Nguyen, H.T., Kuo, G.C., Beutler, B., Cotran, R.S., Cerami, A. and Lowry, S.F. Cachectin/Tumor necrosis factor induces cachexia, anemia, and inflammation, J. Exp. Med. 1988; 167:1211-1227.
21. Yang, Z.J., Koseki, M., Meguid, M.M., Gleason, J.R. and Debonis, D. Synergislic effect of rhTNF-α and rhIL-Iα in inducing anorexia in rats. Amer. J. Physiol. 1994; 267:R1056-64.
22. Tramontana, J.M., Utaipat, U., Molloy, A., Akarasewi, P., Burroughs, M., Makonkawkeyoon, S., Johnson, B., Klausner, J.D., Rom, W. and Kaplan, G. Thalidomide treatment reduces tumor necrosis factor a production and enhances weight gain in patients with pulmonary tuberculosis. Molec. Med. 1995; 1:384-397.
23. Wallis, R.S., Helfend, M.S., Whalen, C.C., Johnson, J.L., Mugerwa, R.D., Vjecha, M., Okwera, A. and Ellner, J.J. Association of macrophage activation with increased mortality in HIV-1-positive tuberculosis. Conference on Global Lung Health and the Annual Meeting of the IUATLD/ UICTMR 1995; Paris, Sept. 9-12, 184-PA12.
24. Mukudi, Y., Perriens, J.H., St Louis, M.E., Brown, C., Prignol, J., Willame, J.C., Pouthier, P., Kaboto, M., Ryder, R.W., Portaels, F. and Piot, P. Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet. 1993;342:143-46.
25. Jones, B.E., Young, S.M.M., Antoniskis, D., Davidson, P.T., Kramer, F. and Harnes, P.F. Relationship of the Manifestations of Tuberculosis to CD4 Cell Counts in patients with Human Immunodeficiency Virus Infection. Amer. Rev Respir. Dis. 1993; 148:1292-1297.
26. Peronne, C., Ghoubontni, A., Leport, C., Salmon-Ceron, D., Bricaire, F. and Vilde, J.L. Should pulmonary tuberculosis be an AIDS-defining diagnosis in patients infected with HIV? Tuber. Lung Dis. 1992; 73:39-44.
27. Lang, W., Perkins, H., Anderson, R.E. Ropyce, R., Jewell, N. and Winkelstein, W. Patterns of T lymphocyte changes with Human Immunodeficiency Virus Infection: From Seroconversion to the Development of AIDS. J. AIDS. 1989; 2:63-69.
28. Ainslie, G.M., Solomon, J.A. and Bateman, E.D. Lymphocyte and lymphocyte subset numbers in blood and in bronchoalveolar lavage and pleural fluid in various forms of human pulmonary tuberculosis at presentation and during recovery. Thorax. 1992; 47:513-518.
29. Turett, G.S. and Telzak, E.E. Normalization of CD4+ T-Lymphocyte Depletion in Patients without HIV Infection Treated for Tuberculosis. Chest. 1994; 105:1335-37.
30. Nunn, P. Cutaneous hypersensitivity reactions due to thioacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 1991; 337:627-630.
31. Okwera, A., Whalen, C., Byekwaso, F., Vjecha, M., Johnson, J., Huebner, R., Mugerwa, R. and Elnner, N. Randomised trial of throacetazone and rifampicin containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet. 1994; 344:1323-1328.
32. Perriens, J.H., St. Louis, M.E., Mukudi, Y.B., Brown, C., Prignot, J., Pouthier, F., Portaels, F., Willame, J.C., Mandala, J.K., Kaboto, M., Ryder, R.W., Roscigno, G. and Plot, P. Pulmonary tuberculosis in HIV-infected patients in Zaire A controlled trial of treatment for either 6 or 12 months. N. Engl. J. Med. 1995; 332:779-84.
33. Ackah, A.N., Coulibaly, D., Digbeu, H., Diallo, K., Vetter, K.M., Coulibaly, I.M., Greenberg, A.E. and De Cock, K.M. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan. Cote d' Ivoire. Lancet. 1995; 345:607-610.